Phase II studies of thalidomide in multiple myeloma have concluded that a higher baseline VEGF levels were associated with response to treatment ((Mileshkin et al, 2007), and clinical responses associated with decreases in VEGF and bFGF levels (Bertolini et al, 2001). This evidence concerns the gene FGF2 and plasma cell myeloma.